HHS Layoffs: Cut to Cure, or Just Cut?
The HHS overhaul is triggering a showdown over public trust, biomedical innovation, and the cost of reform.
Keith Sakata
The Fight Over Affordable GLP-1 Drugs
The FDA's GLP-1 crackdown is fueling a debate over access, safety, and pharma power.